Join Us At SABCS® 2020


Agendia at San Antonio Breast Cancer Symposium®

Agendia will present new data from ongoing clinical research evaluating the MammaPrint and BluePrint genomic tests at the upcoming 2020 San Antonio Breast Cancer Symposium®.

Agendia will present new data from ongoing clinical research evaluating the MammaPrint and BluePrint genomic tests at the upcoming 2020 San Antonio Breast Cancer Symposium®

SABCS® 2020 has illustrated the expanding spectrum of clinical utility for Agendia’s MammaPrint and BluePrint, going well beyond the “chemo/no chemo” question, and highlighted by 5 year outcome data from the innovative neoadjuvant NBRST trial, as well as a biomarker analysis of the APHINITY trial. More information below.

Agendia’s activities at SABCS®:

Product theater with Q&A featuring MINDACT and NBRST updates:

  • Title: Integrating MammaPrint and BluePrint into Pre- and Post-Operative Patient Care
  • Date: Wednesday, December 9 at 10:00 am CST
  • Speaker: William Audeh, MD, Pat Whitworth, MD, David Hicks, MD

Data Highlights

  • Title: BluePrint performance in predicting pertuzumab benefit in genomically HER2-positive patients: a biomarker analysis of the APHINITY trial
    • Authors: Krop, I., et al.
    • Session: Spotlight Poster Discussion 3 | Wednesday, December 9, 2020 | 6:30pm – 7:30pm CST
    • Poster #: PD3-01
  • Title: 5-year outcomes in the NBRST trial: Preoperative MammaPrint and BluePrint breast cancer subtype is associated with neoadjuvant treatment response and survival
    • Authors: Whitworth, P., et al.
    • Session: Spotlight Poster Discussion 9 | Thursday, December 10, 2020 | 3:30pm – 4:45pm CST
    • Poster #: PD9-01.

More Information below.

#IAMHERE

An intimate portrait series that illustrates the essence of 50 people who have been touched by breast cancer – Click here to view campaign.

Virtual Booth

Visit our virtual booth for more information and to speak with a member of our team.


Molecular subtyping by BluePrint improves prediction of treatment responses and survival outcomes in patients with discordant clinical and genomic classification

  • Authors: Whitworth, P., et al.
  • Session: Poster Session 4
  • Poster #: PS4-04

5-year outcomes in the NBRST trial: Preoperative MammaPrint and BluePrint breast cancer subtype is associated with neoadjuvant treatment response and survival

  • Authors: Whitworth, P., et al.
  • Session: Spotlight Poster Discussion 9 | Thursday, December 10, 2020 | 3:30pm – 4:45pm CST
  • Poster #: PD9-01

Racial disparities within Basal-type breast cancer: clinical and molecular features of African American and Caucasian obese patients

  • Authors: Sharma, D., et al.
  • Session: Poster Session 7
  • Poster #: PS7-68

Molecular profiles and clinical-pathological features of Asian early-stage breast cancer patients

  • Authors: Chen, M., et al.
  • Session: Poster Session 7
  • Poster #: PS7-69

Differential gene expression analysis and clinical utility of MammaPrint and BluePrint in male breast cancer patients

  • Authors: Crozier, J., et al.
  • Session: Poster Session 14
  • Poster #: PS14-11

Molecular profiles and clinical-pathological features of Asian early-stage breast cancer patients

  • Authors: Chen, M., et al.
  • Session: Poster Session 7
  • Poster #: PS7-69

Using BluePrint to elucidate the molecular heterogeneity of triple negative breast cancers

  • Authors: Kaklamani, V.G., et al.
  • Session: Poster Session 18
  • Poster #: PS18-05

BluePrint performance in predicting pertuzumab benefit in genomically HER2-positive patients: a biomarker analysis of the APHINITY trial

  • Authors: Krop, I., et al.
  • Session: Spotlight Poster Discussion 3 | Wednesday, December 9, 2020 | 6:30pm – 7:30pm CST
  • Poster #: PD3-01

Comparing MammaPrint and BluePrint results between core needle biopsy and surgical resection breast cancer specimens

  • Authors: McKelley, J., et al.
  • Session: Poster Session 6
  • Poster #: PS6-19

The 70-gene signature (MammaPrint) accurately predicts distant breast cancer recurrence risk in patients aged ≥70 years from the population-based observational FOCUS cohort.

  • Authors: Noordhoek, I., et al.
  • Session: Poster Session 6
  • Poster #: PS6-06

The FLEX real-world data platform explores new gene expression profiles and investigator-initiated protocols in early stage breast cancer

  • Authors: Lee, L., et al.
  • Session: Ongoing Trials Posters
  • Poster #: OT-12-01

MammaPrint and BluePrint as prognostic indicators for elderly patients with early stage breast cancer

  • Authors: Blumencranz, P.W., et al.
  • Session: Poster Session 6
  • Poster #: PS6-41
  • This field is for validation purposes and should be left unchanged.

For the US, Puerto Rico, Canada and South America

Agendia Inc. USA
22 Morgan
Irvine, CA 92618
(888) 321-2732
customercare@agendia.com

 

For outside the Americas

Agendia NV
Radarweg 60
1043 NT Amsterdam
The Netherlands
customerservice@agendia.com
+31 (0)20 462 1510